Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,059.21 +40.82 (+0.81%) Dow
38,187.97 +284.68 (+0.75%) Nasdaq
15,819.20 +213.72 (+1.37%) Bitcoin USD
59,086.38 +1,367.27 (+2.37%) CMC Crypto 200
1,279.01 +8.27 (+0.65%)
Mersana Therapeutics, Inc. (MRSN)
- GlobeNewswire
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024. The company will host a conference call and webcast at 8:00 a.m. Eas
- Zacks
Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
Curis (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- GlobeNewswire
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on April 1, 2024, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 35,100 shares of its common s
